NovaBay Pharmaceuticals Inc.

AMEX: NBYHealthcare / Biotechnology / USA
0.630000.00Vol 291 4781Y Perf -59.74%
Oct 16th, 2019 16:00
BID0.6100 ASK0.6400
Open0.6400 Previous Close0.6300
Pre-Market- After-Trading-
 - -%  - -%
Target Price
1.10 
Analyst Rating
Strong Buy 1.00
Potencial %
74.60 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12M
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-100/-100 
Growth Ranking
     33.25
Insiders Shares Cnt. % 3/6/12M
-/-100/-100 
Income Ranking
 —    -
Market Cap (mil)16 
Earnings Rating
Buy
Price Range Ratio 52wk %
10.50 
Earnings Date
13th Nov 2019

Today's Price Range

0.61000.6600

52wk Range

0.23004.04

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.00%
1 Month
18.87%
3 Months
-50.00%
6 Months
-35.71%
1 Year
-59.74%
3 Years
-83.89%
5 Years
-96.55%
10 Years
-98.65%

Name / TickerPriceChg.Chg.%
NBY0.63000.00000.00
AAPL234.37-0.9500-0.40
GOOG1 243.640.63000.05
MSFT140.41-1.1600-0.82
XOM68.23-1.1900-1.71
WFC49.59-0.5200-1.04
JNJ135.172.33001.75
FB189.550.66000.35
GE8.900.01000.11
JPM119.68-0.2800-0.23
Earnings HistoryEstimateReportedSurprise %
Q02 2019--0.14-
Q01 2019--0.24-
Q04 2018-0.14-0.0935.71
Q03 2018-0.09-0.11-22.22
Q02 2018-0.12-0.15-25.00
Q01 2018-0.07-0.14-100.00
Q04 2017-0.050.02140.00
Q03 2017-0.09-0.16-77.78
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.18-20.00Negative
6/2019 QR-0.0650.00Positive
12/2019 FY-0.47--
12/2020 FY-0.20--
Next Report Date13th Nov 2019
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume291 478
Shares Outstanding (in ths.)25 202
Trades Count269
Dollar Volume180 099
Avg. Volume1 193 667
Avg. Weekly Volume203 381
Avg. Monthly Volume931 615
Avg. Quarterly Volume1 074 326
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
0
0
Moderate Buy
0 (0.00 %)
0
0
Hold
0 (0.00 %)
0
0
Moderate Sell
0 (0.00 %)
0
0
Strong Sell
0 (0.00 %)
0
0
RatingStrong Buy
1.00
--

NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company. The company develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eyecare market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox). NovaBay develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.

CEO: Justin M. Hall

Teplephone: +1 510 899-8800

Address: 2000 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

44%56%

Bearish Bullish

42%58%

Bearish Bullish

58%42%

News